A presentation from the 2008 HIV Health and Treatments Update forum held in Sydney on 25 Nov 2008.
Part 4: a look at HIV drugs in development, presented by Bill Whittaker.
Five drug development strategies to combat SARS-CoV2Anton Yuryev
Slides were presented at webinar on “Opportunities & Challenges in Drug Discovery and Development” organised by Elsevier in collaboration with Dr Reddy’s Institute of Life Sciences, Hyderabad on July 16th,2020
HCV Alerts- Rapid Response to Practice-Changing Advances From EASL 2015Hivlife Info
In this downloadable slideset, Mark S. Sulkowski, MD, discusses key practice-changing data from the 2015 liver disease meeting in Vienna.
Format: Microsoft PowerPoint (.ppt)
File size: 751 KB
General Investor and partnership presentation for the launch of a new pharmaceutical product. Specifically funds the initial clinical trial and market tests.
Slides to Guide Management of Patients With HCV/HIV Coinfection.2018hivlifeinfo
Slides to Guide Management of Patients With HCV/HIV Coinfection.2018
Gain expert perspective on selecting optimal DAA and ARV combinations for patients with HCV/HIV coinfection in this downloadable slideset.
Mark S. Sulkowski, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 327 KB
Released: July 20, 2018
Ủy ban WHO về tiêu chuẩn hóa chất lượng chế phẩm sinh học nằm trong bộ Technical Report Series no 999. Xem thêm các tài liệu khác trên kênh của Công ty Cổ phần Tư vấn Thiết kế GMP EU.
Our profound expertise in neuroscience and more than a
decade of experience in contract research results in a sustainable advantage for our customers. We offer you a sophisticated range of validated transgenic and non-transgenic in vivo and in vitro models in order to make sure that your new chemical or biological entities get profiled in depth using both novel and established drug targets that may play a role in the complex etiology of neuro-degenerative disease.
Five drug development strategies to combat SARS-CoV2Anton Yuryev
Slides were presented at webinar on “Opportunities & Challenges in Drug Discovery and Development” organised by Elsevier in collaboration with Dr Reddy’s Institute of Life Sciences, Hyderabad on July 16th,2020
HCV Alerts- Rapid Response to Practice-Changing Advances From EASL 2015Hivlife Info
In this downloadable slideset, Mark S. Sulkowski, MD, discusses key practice-changing data from the 2015 liver disease meeting in Vienna.
Format: Microsoft PowerPoint (.ppt)
File size: 751 KB
General Investor and partnership presentation for the launch of a new pharmaceutical product. Specifically funds the initial clinical trial and market tests.
Slides to Guide Management of Patients With HCV/HIV Coinfection.2018hivlifeinfo
Slides to Guide Management of Patients With HCV/HIV Coinfection.2018
Gain expert perspective on selecting optimal DAA and ARV combinations for patients with HCV/HIV coinfection in this downloadable slideset.
Mark S. Sulkowski, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 327 KB
Released: July 20, 2018
Ủy ban WHO về tiêu chuẩn hóa chất lượng chế phẩm sinh học nằm trong bộ Technical Report Series no 999. Xem thêm các tài liệu khác trên kênh của Công ty Cổ phần Tư vấn Thiết kế GMP EU.
Our profound expertise in neuroscience and more than a
decade of experience in contract research results in a sustainable advantage for our customers. We offer you a sophisticated range of validated transgenic and non-transgenic in vivo and in vitro models in order to make sure that your new chemical or biological entities get profiled in depth using both novel and established drug targets that may play a role in the complex etiology of neuro-degenerative disease.
This presentation shows how Risk Based Decision Making was performed on a real project (which won an international call for bids), using Riskope's CDA/ESM project evaluation methodology.
Line Upgrade Deferral Scenarios for Distributed Renewable Energy ResourcesIain Sanders
This project examined the economic viability of using distributed renewable resources to defer costly electricity distribution network upgrades in rural areas using information provided by three independent electricity distribution networks.
This example, that we presented at the WLF2 Conference in Rome, constitutes a complete and fully developed which included the following phases:
probabilistic behaviour forecast,
behaviour monitoring (which luckily allowed to actually “see happen” what we had predicted a few years earlier),
Risk Based Decision Making (RBDM), and finally
implementation of mitigative and crisis management plan.
Interestingly, in a curious turn of events, while doing some reconnaissance work on the landslide, two of us almost lost our lives in a helicopter crash. Risk managers are unfortunately not immune to risks...and somehow it was a good lesson for us to be in the “victim role” that day.
The Sociology of Nothingness: Challenges of Big DataEugen Glavan
The Sociology of Nothingness: Challenges of Big Data
Presentation at Towards the Good Society – European Perspectives Conference, Bucharest, 2013
Eugen Glăvan
Abstract
The recent evolution of the internet caught attention of the social researchers through increased interaction among individuals in various aspects of life mediated by electronic devices. The boundaries between digital and real life become blurred and we are witnessing the accumulation of abundant, detailed and comprehensive information about a wide range of behaviours, choices, opinions and artefacts of Internet users. Whether we are talking about images on Flickr, short texts on platform Twitter, search log files generated by Google, millions of megabytes of information form databases on which the issue is not capability of computing, but how to analyse such data methodologically. In my presentation I will describe the latest information concerns the definition and use of „Big Data”, showing the applications and theories developed so far and possible directions for use and development of digital sociology through these types of information.
Keywords: big data, internet, digital sociology
Presentation given on May 6th at CIM 2013 Toronto.
A discussion on the reasons that lead to the generalized public distrust phenomena, how better risk assessments would help reduce distrust and support better decisions.
Presentation: What's trending in medicines regulation? A January 2017 reflectionTGA Australia
This presentation provides a local perspective on recent developments in the medical technology and pharmaceutical landscape, and the future of the TGA in a global context.
Lustrumlezing paul stoffels de rol van innovatie voor de gezondheidszorg van ...Michiel Stoffels
Ter gelegenheid van het 40 jarig bestaan van de Universiteit werd een reeks lustrumlezingen georganiseerd. Voor de faculteit Gezondheid en Levenswetenschappen hadden we de eer Dr. Paul Stoffels - Worldwide Chairman , Janssen Pharmaceutical Chief Scientific Officer, Johnson & Johnson - te mogen ontvangen.
This presentation shows how Risk Based Decision Making was performed on a real project (which won an international call for bids), using Riskope's CDA/ESM project evaluation methodology.
Line Upgrade Deferral Scenarios for Distributed Renewable Energy ResourcesIain Sanders
This project examined the economic viability of using distributed renewable resources to defer costly electricity distribution network upgrades in rural areas using information provided by three independent electricity distribution networks.
This example, that we presented at the WLF2 Conference in Rome, constitutes a complete and fully developed which included the following phases:
probabilistic behaviour forecast,
behaviour monitoring (which luckily allowed to actually “see happen” what we had predicted a few years earlier),
Risk Based Decision Making (RBDM), and finally
implementation of mitigative and crisis management plan.
Interestingly, in a curious turn of events, while doing some reconnaissance work on the landslide, two of us almost lost our lives in a helicopter crash. Risk managers are unfortunately not immune to risks...and somehow it was a good lesson for us to be in the “victim role” that day.
The Sociology of Nothingness: Challenges of Big DataEugen Glavan
The Sociology of Nothingness: Challenges of Big Data
Presentation at Towards the Good Society – European Perspectives Conference, Bucharest, 2013
Eugen Glăvan
Abstract
The recent evolution of the internet caught attention of the social researchers through increased interaction among individuals in various aspects of life mediated by electronic devices. The boundaries between digital and real life become blurred and we are witnessing the accumulation of abundant, detailed and comprehensive information about a wide range of behaviours, choices, opinions and artefacts of Internet users. Whether we are talking about images on Flickr, short texts on platform Twitter, search log files generated by Google, millions of megabytes of information form databases on which the issue is not capability of computing, but how to analyse such data methodologically. In my presentation I will describe the latest information concerns the definition and use of „Big Data”, showing the applications and theories developed so far and possible directions for use and development of digital sociology through these types of information.
Keywords: big data, internet, digital sociology
Presentation given on May 6th at CIM 2013 Toronto.
A discussion on the reasons that lead to the generalized public distrust phenomena, how better risk assessments would help reduce distrust and support better decisions.
Presentation: What's trending in medicines regulation? A January 2017 reflectionTGA Australia
This presentation provides a local perspective on recent developments in the medical technology and pharmaceutical landscape, and the future of the TGA in a global context.
Lustrumlezing paul stoffels de rol van innovatie voor de gezondheidszorg van ...Michiel Stoffels
Ter gelegenheid van het 40 jarig bestaan van de Universiteit werd een reeks lustrumlezingen georganiseerd. Voor de faculteit Gezondheid en Levenswetenschappen hadden we de eer Dr. Paul Stoffels - Worldwide Chairman , Janssen Pharmaceutical Chief Scientific Officer, Johnson & Johnson - te mogen ontvangen.
The presentation defines brief introduction of anti HIV agents as well as anti mycobacterial agent including Structures, SAR, mode of action, adverse effects.
Most current highly active antiretroviral therapy (HAART) regimens for HIV-positive patients contain two nucleoside reverse transcriptase inhibitors (NRTIs) with either a Protease inhibitor (PIs) or a non-nucleoside reverse transcriptase inhibitors (NNRTI). Notwithstanding the regulatory guidelines recommending therapeutic drug monitoring (TDM) for these drugs, therapeutic failure is a very serious concern implying drug induced toxicity and more importantly viral rebound and viral resistance.
Single dose, steady state and dose ranging studies have all more or less demonstrated that there is a positive correlation between plasma concentrations and therapeutic effects of anti-retrovirals (ARVs). However, one of the main challenges still seems to be the target concentrations for these drugs and their relevant inhibitory quotient. In this talk, we are going to examine these issues along with bioanalytical challenges, drug-effect and drug –toxicity relationships and finally drug-drug interactions within different HAART regimes.
This is a training on the research and development pipeline for new HIV prevention technologies - including PrEP, microbicides, and new male and female condoms. It was conducted by AIDS Foundation of Chicago's Jim Pickett in partnership with the Illinois Public Health Association, on Monday, September 29, 2014 in Bloomington, Illinois.
It is essential to diagnosis and the Treatment of HIV virus disease.
That presentation contains the management of HIV and also the classification of antiviral drugs.HIV symptoms and treatments.
Treatment for Older, Children as well as pregnant women.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Best Ayurvedic medicine for Gas and IndigestionSwastikAyurveda
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Part 4: New HIV Treatment Pipeline
1.
2. HIV Treatment and Health Update 25 November 2008 Part 4 New HIV treatment pipeline
3.
4.
5.
6. “ The white ones help my immune system but raise my blood pressure. The red ones lower my blood pressure but screw up my stomach. The green ones help my stomach but fuck with my immune system. Then these yellow ones simply ensure an attractive colour combination.”
7.
8.
9.
10.
11. Nucleosides eg. 3TC Non-Nucleosides eg. Efavirenz Fusion eg. T20 Proteases eg. Kaletra CD4 T-Cell HIV antiviral drugs interrupt the making of new HIV virus Maturation Integrase eg. Raltegravir
16. CCR5 blocker CCR5 CD4 T cell surface This HIV virus particle…….gives up and goes away…..
17.
18. 2008 Experimental HIV Antiviral Drugs Clinical Trials in People RTV like booster Gilead Phase II Enhancer GS 93502 RTV like booster Sequoia Phase I Enhancer SPI-452 Genentech Phase II CD4 TNX-355 Progenics Phase II CCR5 PRO 140 Phase I Aust. Schering Phase I CCR5 SCH532706 Schering Phase III CCR5 Vicriviroc Tobira Phase I CCR5 TBR-652 Gilead Phase II Integrase Elvitegravir Panacos Phase I/II Maturation Beviramat (PA-457) Sequoia Phase I/II Protease I SPI-256 Ardea Phase I/II Non-NRTI RDEA806 Tibotec/JJ Phase III Non-NRTI Rilpivirine (TMC-278) Pfizer Phase I/II Non-NRTI UK-453,061 Idenix Phase I/II Non-NRTI IDX899 Achillion Phase II NRTI Elvucitabine RFS Phase II NRTI Amdoxovir Australian Avexa Phase III NRTI Apricitabine Comment Pharma Clinical Trial progress Target Drug
21. NEW ARV PIPELINE: Timelines for First Access Beviramat Panacos TNX 355 Genentech NO NEW INFO for some years SO DROP GS1937 Gilead AVX754 Apricitabine Avexa DISCONTINUED Reverset Pharmasset STALLED Racivir Pharmasset TMC-278 Rilpivirine Tibotec APPEARS DISCONTINUED BILR-355 BMS DISCONTINUED INCB9471 Incyte Corp Recently put on hold KP-1461 Koronis Protease Inhibitors NNRTIs (Non Nukes) NRTIs (Nukes) Maturation inhibitor Integrase inhibitors Entry inhibitors 2012 2011 2010 2009 2008 DISCONTINUED GW 640385 Brecanavir GSK